PL1831402T3 - Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę - Google Patents

Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę

Info

Publication number
PL1831402T3
PL1831402T3 PL05855433T PL05855433T PL1831402T3 PL 1831402 T3 PL1831402 T3 PL 1831402T3 PL 05855433 T PL05855433 T PL 05855433T PL 05855433 T PL05855433 T PL 05855433T PL 1831402 T3 PL1831402 T3 PL 1831402T3
Authority
PL
Poland
Prior art keywords
vkorc1
genetic variants
polymorphism
warfarin sensitivity
warfarin
Prior art date
Application number
PL05855433T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Hsiang-Yu Yuan
Jin-Jer Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1831402(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of PL1831402T3 publication Critical patent/PL1831402T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL05855433T 2004-12-21 2005-12-21 Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę PL1831402T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63883704P 2004-12-21 2004-12-21
US67969405P 2005-05-10 2005-05-10
PCT/US2005/046869 WO2006069339A2 (en) 2004-12-21 2005-12-21 Genetic variants of vkorci predicting warfarin sensitivity
EP05855433A EP1831402B1 (en) 2004-12-21 2005-12-21 Genetic variants of vkorc1 predicting warfarin sensitivity

Publications (1)

Publication Number Publication Date
PL1831402T3 true PL1831402T3 (pl) 2010-12-31

Family

ID=36602356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05855433T PL1831402T3 (pl) 2004-12-21 2005-12-21 Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę

Country Status (18)

Country Link
US (2) US20060166239A1 (pl)
EP (2) EP1831402B1 (pl)
JP (1) JP4516990B2 (pl)
KR (1) KR101178463B1 (pl)
CN (1) CN101142322B (pl)
AT (1) ATE470725T1 (pl)
AU (1) AU2005319028B2 (pl)
BR (1) BRPI0519570A2 (pl)
CA (1) CA2591840C (pl)
DE (1) DE602005021821D1 (pl)
DK (1) DK1831402T3 (pl)
ES (1) ES2347167T3 (pl)
MX (1) MX2007007568A (pl)
NZ (1) NZ556461A (pl)
PL (1) PL1831402T3 (pl)
PT (1) PT1831402E (pl)
TW (1) TWI334886B (pl)
WO (1) WO2006069339A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
US8380539B2 (en) * 2006-05-09 2013-02-19 University Of Louisville Research Foundation, Inc. Personalized medicine management software
US8039212B2 (en) * 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2010048020A1 (en) * 2008-10-20 2010-04-29 Epitome Pharmaceuticals Limited Methods and systems for improved pharmaceutical intervention in coagulation control
KR101157135B1 (ko) * 2008-12-29 2012-06-18 인제대학교 산학협력단 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법
US20100227776A1 (en) * 2009-03-05 2010-09-09 The Ohio State University Rapid Genotyping of SNPs
CN102268476B (zh) * 2010-06-01 2014-02-19 爱科来株式会社 Vkorc1基因的第-1639位碱基的多态性检测方法、以及用于该方法的核酸探针和试剂盒
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US9290799B2 (en) * 2012-08-21 2016-03-22 Industrial Technology Research Institute System and method for detecting biological materials
CN103173443B (zh) * 2013-03-22 2016-08-24 卫生部北京医院 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用
CN110506128A (zh) 2016-12-09 2019-11-26 博德研究所 基于crispr效应系统的诊断
KR20190140918A (ko) 2017-03-15 2019-12-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 검출을 위한 crispr 이펙터 시스템 기반 진단
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
US10249389B2 (en) * 2017-05-12 2019-04-02 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
AU2019213047B2 (en) 2018-01-29 2025-07-24 Massachusetts Institute Of Technology CRISPR effector system based diagnostics
WO2020186223A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Sherlock assays for tick-borne diseases
CN110592206A (zh) * 2019-09-11 2019-12-20 上海交通大学 一种利用rs9934438检测华法药效的试剂盒
KR102506347B1 (ko) 2021-05-11 2023-03-03 충북대학교 산학협력단 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006044686A2 (en) * 2004-10-18 2006-04-27 University Of Washington Methods and compositions for predicting drug responses
US20080005732A1 (en) * 2006-05-11 2008-01-03 Coon Robert F Method and System for Integrating Software Update Services with Software Applications

Also Published As

Publication number Publication date
AU2005319028B2 (en) 2010-09-16
CA2591840C (en) 2012-07-10
TW200637918A (en) 2006-11-01
KR101178463B1 (ko) 2012-09-07
CN101142322A (zh) 2008-03-12
BRPI0519570A2 (pt) 2009-01-27
EP1831402B1 (en) 2010-06-09
AU2005319028A1 (en) 2006-06-29
DE602005021821D1 (de) 2010-07-22
HK1117571A1 (en) 2009-01-16
DK1831402T3 (da) 2010-09-20
WO2006069339A3 (en) 2006-10-12
TWI334886B (en) 2010-12-21
CA2591840A1 (en) 2006-06-29
WO2006069339A2 (en) 2006-06-29
ES2347167T3 (es) 2010-10-26
NZ556461A (en) 2009-12-24
JP4516990B2 (ja) 2010-08-04
WO2006069339A8 (en) 2010-06-03
CN101142322B (zh) 2011-09-21
KR20080005179A (ko) 2008-01-10
ATE470725T1 (de) 2010-06-15
EP1831402A2 (en) 2007-09-12
US20060166239A1 (en) 2006-07-27
US20110236885A1 (en) 2011-09-29
JP2008523844A (ja) 2008-07-10
PT1831402E (pt) 2010-09-10
EP2246445A1 (en) 2010-11-03
MX2007007568A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
PL1831402T3 (pl) Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę
IL182519A0 (en) Methods and compositions for predicting drug responses
DK1842920T3 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
DE602005013153D1 (de) Assoziation von SNPs in PPAR gamma mit Osteoporose
WO2008048119A3 (en) Methods of analysis of polymorphisms and uses thereof
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
NZ588037A (en) Serotonin transporter gene SLC6A4 and treatment of alcoholism
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
SG191078A1 (en) Improved method and kit for determining severity and progression of periodontal disease
ZA200710910B (en) Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
GB0416044D0 (en) Spinning disc reactor with shroud or plate for improving gas/liquid contact
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2008048902A3 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
WO2010014905A3 (en) Polymorphisms in the xbp-1 gene associated with inflammatory bowel disease
WO2011020075A3 (en) Amelogenin snp on chromosome x
TW200510546A (en) Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
GB2426584A (en) Itpase gene polymorphisms associated with adverse drug reactions to azathioprine
CA2686874C (en) Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment
PL1673472T3 (pl) Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki
RU2005103200A (ru) Способ прогнозирования развития сахарного диабета типа 1 в популяциях народов башкортостана
WO2008042762A3 (en) Single nucleotide polymorphisms associated with cardiovascular disease
ES2344396A1 (es) Marcadores geneticos del riesgo de sufrir reestenosis.
WO2005108624A3 (en) Use of hla-g genotyping in immune-mediated conditions